| Document |
Document Title |
|
WO/2018/170236A9 |
The invention relates to inhibitors of calcium-dependent protein kinase 1 (CDPKl) and pharmaceutical preparations thereof. The invention further relates to methods of treatment of parasitic infections, such as T. gondii, T. cruzi, P. fal...
|
|
WO/2019/013273A1 |
The present invention provides: a compound represented by formula (I), which is highly effective in controlling harmful arthropods; an intermediate of the compound; and a production method for the compound. [In formula (I), A1 represents...
|
|
WO/2018/041942A9 |
Embodiments of the invention are directed to new polymer linked multimeric guanosine-3', 5'-cyclic monophosphate (cGMP) analogues that modulate the cGMP-signaling system, preferably having activating properties, and more preferably being...
|
|
WO/2019/008272A1 |
The present invention concerns a mutant strain of Sarcocystidae in which the two genes mic1 and mic3 are deleted, containing two specific recombination sites of an enzyme enabling a specific recombination in particular Cre recombinase, s...
|
|
WO/2019/008027A1 |
The present disclosure relates to compounds of formula (I) or a pharmaceutically acceptable salt thereof wherein R1 means a fluorine atom or a perhalogeno linear alkyl radical containing 1, 2 or 3 carbon atoms; R2 means a chlorine atom, ...
|
|
WO/2019/008273A1 |
The present invention relates to a mutant strain of Sarcocystidae in which the function of the MIC1 protein and the function of the MIC3 protein are suppressed, for use in the prevention of infectious diseases in poultry.
|
|
WO/2019/010181A1 |
Methods are provided for treating a subject with for an intracellular pathogen infection, by administering an agent that masks or otherwise blocks phosphatidylserine on the pathogen cell surface.
|
|
WO/2019/002132A1 |
The present invention covers azaquinoline compounds of general formula (I), with A being (A1) or (A2), and in which T, R1, R2, R3, R4, R5, R6, and Q are as defined herein, methods of preparing said compounds, intermediate compounds usefu...
|
|
WO/2018/229084A1 |
The present invention relates to a composition useful for the prevention and treatment of disorders of the external portion of the eye, in particular of blepharitis.
|
|
WO/2018/230555A1 |
The present invention provides a compound represented by formula (1)( in formula (I), R1 represents a substituted or unsubstituted C1-6 alkyl group; R2 represents a substituted or unsubstituted C1-8 alkyl group; R3 represents a hydrogen ...
|
|
WO/2018/229683A1 |
The present invention provides a compound of Formula (I), or a pharmaceutically acceptable salt or stereoisomer thereof; (I) a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention furth...
|
|
WO/2018/220531A1 |
The present invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof; (I) a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a com...
|
|
WO/2018/221720A1 |
The present invention provides: a heterocyclic compound and an intermediate thereof, the compound having an excellent controlling effect against harmful arthropods and being represented by formula (I) (in the formula, R2 represents a C1-...
|
|
WO/2018/220176A1 |
The invention relates to chemical compounds that are useful in the treatment of diseases associated with an activity of a 5,10-methylenyltetrahydrofolate cyclohydrolase / 5,10-methylene tetrahydrofolate dehydrogenase enzyme in pathologic...
|
|
WO/2018/217897A1 |
Disclosed herein is an immunogenic comprising an antigen and optionally IL-12. Also disclosed herein is a method for administering the vaccine through intradermal electroporation.
|
|
WO/2018/217807A1 |
Compositions and methods for treating or reducing the severity of occurrence of a parasitic worm or helminth infection in a subject are described. The methods include administering to the subject a therapeutically effective amount of a c...
|
|
WO/2018/211114A1 |
The present invention relates to a high-purity oligosaccharide for use as a drug and to a pharmaceutical composition which contains the high-purity oligosaccharide according to the invention.
|
|
WO/2018/205010A1 |
Phosphorylated heptose compounds are useful in modulating an immune response in a subject. Also, the compounds are useful as adjuvants.
|
|
WO/2018/208595A1 |
Disclosed are compounds of Formula 1, including ail geometric and stereoisomers, N-oxides, and salts thereof, wherein A, X, Y, Z, R1, R2a, R2b and Q are as defined in the disclosure. Also disclosed are compositions containing the compoun...
|
|
WO/2018/205009A1 |
Processes for the preparation of phosphorylated heptose compounds are provided. Embodiments of the invention relate to the chemical synthesis of heptopyranose phosphate compounds. Also, embodiments of the invention relate to the use of c...
|
|
WO/2018/207847A1 |
The present invention provides: a pyrazole-3-carboxylic acid amide derivative having an excellent pest control effect or a salt thereof; and a pest control agent which contains this pyrazole-3-carboxylic acid amide derivative as an activ...
|
|
WO/2018/202524A1 |
The invention relates to compounds of formula (I), wherein Z, Y, A1, A2, A3, A4, X, R7, R8 and R9 have the above-mentioned meanings, and to methods and intermediate products for the production and use thereof for controlling animal pests...
|
|
WO/2018/204563A1 |
The present invention relates to the field of malaria. More specifically, the present invention provides compositions and methods useful for the prophylaxis and treatment of malaria, as well as other parasitic and fungal infections. In a...
|
|
WO/2018/202897A1 |
The invention relates to various compositions, including pharmaceutical compositions comprising an oxidation agent selected from sodium, potassium, magnesium or calcium hypochlorite, chlorite or chlorate, an artemisinin composition or a ...
|
|
WO/2018/201196A1 |
A composition or medicament including an extract of Terminalia ferdinadiana (T. ferdinandiana) as an antimicrobial or antibacterial agent for use in treating microbiasl/bacterial infection in humans or animals, preferably B. anthracis or...
|
|
WO/2018/199208A1 |
The present invention addresses the problem of developing and providing a novel insecticide for agriculture and horticulture in response to the occurrence of pests resistant to existing chemicals, etc., since there is still large damage ...
|
|
WO/2018/198021A1 |
The present invention relates to dosing regimen of a new antimalarial drug, as monotherapy or combination therapy.
|
|
WO/2018/200812A1 |
Provided herein are immunoconjugates comprising STING agonists. Also disclosed are methods of making the immunoconjugates and methods of treating cancer using the immunoconjugates.
|
|
WO/2018/193063A2 |
The present invention provides a fragment of piasmodium circumsporozoite protein according to SEQ ID NO: 1, for example for use in a malaria vaccine. The present invention also provides nucleic acids encoding a fragment of piasmodium cir...
|
|
WO/2018/189490A1 |
The invention relates to microcapsules intended to protect probiotics, comprising a shell and a core wherein the probiotics are dispersed in the form of biofilms distributed in distinct clusters, characterised in that the shell and the c...
|
|
WO/2018/189314A1 |
The present invention relates to an injectable implant comprising an effective amount of a macrocyclic lactone, or a salt thereof, and a bioresorbable polymer, and its use in preventing and/or treating parasites infestations in non human...
|
|
WO/2018/190321A1 |
A compound represented by formula (1), or a salt thereof, is provided that is effective as a parasitic pest control agent. In the formula, R1 represents an optionally substituted C1-C6 alkyl group, a C1-C6 haloalkyl group, etc., R2 repre...
|
|
WO/2018/185685A1 |
The present invention relates to a topical pharmaceutical composition comprising: at least two pharmaceutical agents selected from the group consisting of pentamidine isethionate, ketoconazole and miltefosine; an agent for boosting skin ...
|
|
WO/2018/187623A1 |
The present invention provides crystalline forms of compound of formula (la) and processes of making the crystalline forms. Also provided are compositions comprising the crystalline forms and crystalline forms for treating or preventing ...
|
|
WO/2018/185346A1 |
The invention relates to a pharmaceutical composition for systemic, particularly parenteral treatment of infectious diseases, based on an aqueous, sterile and pyrogen-free solution of chlorine dioxide, which contains 5 to 1000 mg/l (ppm)...
|
|
WO/2018/182523A1 |
The present invention relates to a vaccine for therapeutic or prophylactic treatment of a pathological condition. In particular, the present invention relates to a vaccine for therapeutic or prophylactic treatment of malaria. In an aspec...
|
|
WO/2018/176079A1 |
This invention relates to berberine alkaloids, formulations thereof and their use for the prevention and/or treatment of infectious disease, especially disease caused by C. perfringens and Eimeria in animals. The invention also relates t...
|
|
WO/2018/183922A1 |
The present invention provides methods and compositions for immunizing a subject against malaria.
|
|
WO/2018/176093A1 |
This invention relates to berberine alkaloids, formulations thereof, and their use in the prevention and/or treatment of infectious disease in animals, particularly Lawsonia infection. In particular, the invention relates to berberine al...
|
|
WO/2018/183512A1 |
A single-dose oral formulation of spinosad and lufenuron and methods for its use in the extended control of a flea infestation on a domestic animal such as a dog without emesis.
|
|
WO/2018/178345A1 |
The present invention is directed to a salt of a compound of formula (I), R1 is halogen or methyl; X is methyl, OR2, or SR2; Y1, Y2 is CR3 or N, and one of Y1, Y2 is N and one of Y1, Y2 is CR3; R2 is methyl or ethyl; R3 is hydrogen or me...
|
|
WO/2018/175633A1 |
Provided herein are methods and compositions for vaccinating subjects against malaria, or otherwise promoting the development of an immune response against Plasmodium falciparum. In some aspects, provided here are compositions comprising...
|
|
WO/2018/174170A1 |
A compound represented by formula (I) has an excellent controlling effect on arthropod pests. (In the formula, Q represents a group represented by formula Q1 or the like; A1 represents CR7 or the like; A2 represents NR8A or the like; A4 ...
|
|
WO/2018/167271A1 |
The present invention is related to a stable topical veterinary composition comprising:• a) selamectin, • b) dimethyl sulfoxide (DMSO) in an amount between 0.5-15% w/v,• c) an organic solvent and • d) optionally an antioxidant.
|
|
WO/2018/167385A1 |
The present invention relates to a composition comprising pyrethrum for the control of target arthropod pests on a human or animal to be treated. The composition comprises a synergic mixture as an active agent, consisting of pyrethrum, a...
|
|
WO/2018/166427A1 |
Provided are a Streptomyces avermitilis strain C63-51 with a high yield of ivermectin B1b and a method for producing ivermectin B1b by using this strain. By using the above-mentioned strain and method, efficient production of single iver...
|
|
WO/2018/161291A1 |
Provided in the present invention is an eprinomectin nanoemulsion, the eprinomectin nanoemulsion containing eprinomectin, a solvent and a long-chain monoester; the monoester is represented by the formula R-COO-R', wherein R is selected f...
|
|
WO/2018/161938A1 |
A gynecological vaginal wash for adjusting female vaginal microecology and a preparation method thereof. The wash is prepared by adding a natural fragrance to acidic water with an acidic water volume concentration of 0.01-0.5% and adjust...
|
|
WO/2018/162312A1 |
The present invention relates to novel spiro compounds of formula I, wherein the variables have the meanings as defined in the specification, to compositions comprising them, to active compound combinations comprising them, and to their ...
|
|
WO/2018/160845A1 |
This application describes compounds, compositions, and methods which are useful in treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a parasite.
|
